25-HYDROXYERGOCALCIFEROL-

Summary

25-Hydroxyergocalciferol- (CHEMBL5095206) is a phase-3 clinical-stage small-molecule bone density conservation agent.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 3
• Chemistry: 412.6 Da · C28H44O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095206
Name	25-HYDROXYERGOCALCIFEROL-
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5710148
ChEBI	CHEBI:86319
Molecular formula	C28H44O2
Molecular weight	412.6
InChIKey	KJKIIUAXZGLUND-ICCVIKJNSA-N

SMILES: C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C

IUPAC name: (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

ChEBI definition: A hydroxycalciol that is vitamin D2 in which the hydrogen at position 25 has been replaced by a hydroxy group.

Pharmacological roles (ChEBI): bone density conservation agent, nutraceutical.

Other ChEBI roles (chemical / environmental): human xenobiotic metabolite.

Also known as: Ercalcidiol

Patent coverage: 616 distinct patent families (1,824 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05306704	PHASE3	COMPLETED	High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial
NCT01398202	Not specified	COMPLETED	Dietary Supplementation With 25-hydroxyvitamin D3 in Older Adults
NCT03334136	Not specified	COMPLETED	The Effect of Vitamin D Supplementation on Psoriasis Severity

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).